| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | STRM | Common Stock, $0.01 par value | 584K | Feb 7, 2024 | Direct | F1 | |||||
| holding | STRM | Common Stock, $0.01 par value | 4.93M | Feb 7, 2024 | Refer to footnote. | F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | STRM | Warrant (right to buy) | Award | $175K | +461K | $0.38 | 461K | Feb 7, 2024 | Common Stock, $0.01 par value | 461K | $0.38 | Refer to footnote. | F4, F5 |
| Id | Content |
|---|---|
| F1 | The reported securities represent shares owned directly by Mr. Ferayorni. |
| F2 | The reported securities represent 4,244,334 shares held directly by Tamarack Global Healthcare Fund, L.P. ("Fund 1") and 686,548 shares held directly by Tamarack Global Healthcare Fund QP, L.P. ("Fund 2"). Tamarack Capital Management, LLC is the general partner of Fund 1 and Fund 2, Tamarack Advisors, LP is the investment advisor to Fund 1 and Fund 2, and Justin J. Ferayorni is the sole managing member of both Tamarack Capital Management, LLC and Tamarack Capital GP, LLC. Tamarack Capital Management, LLC, Tamarack Advisors, LP, and Mr. Ferayorni may be deemed indirect beneficial owners of the shares held by Fund 1 and Fund 2 for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). |
| F3 | Tamarack Capital Management, LLC, Tamarack Advisors, LP, and Mr. Ferayorni disclaim beneficial ownership of any of the shares held by Fund 1 and Fund 2 for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(v) and (vii) under the Act. To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund 1 and Fund 2 for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, if any. |
| F4 | Reflects a warrant to purchase 460,526 shares of the Issuer's common stock, par value $0.01 per share, acquired in connection with a private placement offering by the Issuer. The Warrant has an exercise price of $0.38 per share, is exercisable immediately, and will expire on February 7, 2028. |
| F5 | The reported securities are owned directly by The Ferayorni Family Trust for which Mr. Ferayorni serves as trustee. |